Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Biologics

Guselkumab Studied to Treat RA, Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  September 15, 2015

Guselkumab Studied to Treat RA & Plaque Psoriasis Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA). On June 11, 2015, at the 2015 meeting of the European League Against…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsDrugsguselkumaboutcomeplaque psoriasisRheumatoid arthritisrheumatologySafety

EULAR 2015: Cardiovascular Concerns, Infertility in RA

Thomas R. Collins  |  September 15, 2015

ROME, Italy—In what researchers say is the first study evaluating cardiac magnetic resonance (CMR) findings in early rheumatoid arthritis (ERA) patients, cardiovascular abnormalities were significantly worse in patients with ERA than in matched, healthy controls. The study results were presented at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). Cardiovascular Concerns…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:cardiovascularinfertilityoutcomepatient careRARheumatoid arthritis

Lupus Nephritis Therapies Compared, Plus Naming Guidance for Biosimilars

Michele B. Kaufman, PharmD, BCGP  |  September 9, 2015

Comparing tacrolimus, mycophenolate mofetil and cyclophosphamide, tacrolimus was the most efficacious. Also, biosimilars may soon be easier to differentiate…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologics & BiosimilarscyclophosphamideFDAFood and Drug AdministrationLabeling ChangesLupus nephritismycophenolate mofetiltacrolimus

Arthritis May Be Worse in Poor Countries, but Seem Worse in Rich Ones

Janice Neumann  |  September 6, 2015

(Reuters Health)—A study of people with rheumatoid arthritis (RA) finds that those in wealthy nations are more troubled by it, even though people in poor countries have more severe symptoms. The results, tallied from 17 countries, suggest that cultural factors may influence patients’ perception of their illness, and possibly even the results of clinical trials…

Filed under:ConditionsRheumatoid Arthritis

Use Behavioral ‘Nudging’ to Tackle Gender, Health Challenges

Joseph D'Urso  |  September 4, 2015

LONDON (Thomson Reuters Foundation)—Many of the world’s biggest challenges, such as encouraging people to buy life-saving drugs or unpicking deeply rooted sexism, can be tackled by using subtle psychological cues to change the way people behave, according to experts in London. Behavioral economics, also known as “nudging,” is about making people more likely to make…

Filed under:Practice SupportProfessional TopicsWorkforce Tagged with:adherencemedication compliancepsychologicalpsychosocial

Novartis Launches First U.S. Biosimilar Drug at 15% Discount

Ben Hirschler & Michael Shields  |  September 4, 2015

LONDON/ZURICH (Reuters)—Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first biosimilar copy of a biotechnology drug approved in the U.S., at a discount of 15% to the original. The Swiss drugmaker’s generics unit Sandoz said Zarxio, its form of Amgen’s white blood cell-boosting product Neupogen (filgrastim), would…

Filed under:Biologics/DMARDsDrug Updates Tagged with:AmgenBiologics & BiosimilarsfilgrastimNovartis

FDA Warns of Severe Joint Pain Risk with DPP-4 Diabetes Drugs

Reuters Staff  |  August 31, 2015

(Reuters)—A class of diabetes drugs that include Merck & Co Inc.’s Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday. The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006,…

Filed under:Drug Updates Tagged with:FDAjointJoint Pain

Early, Aggressive Therapy for RA May Result in Cost Savings Long Term

Lara C. Pullen, PhD  |  August 31, 2015

By considering the long-term damage from early, aggressive rheumatoid arthritis, researchers in the UK were able to develop a model demonstrating the long-term cost effectiveness of more aggressive combination therapies v. short-term treatments…

Filed under:ConditionsRheumatoid Arthritis Tagged with:adalimumabcombination therapyDisease-modifying antirheumatic drugs (DMARDs)healthcare costMethotrexateRheumatiod arthritis

FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names

Toni Clarke  |  August 28, 2015

WASHINGTON (Reuters)—The U.S. Food and Drug Administration proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts. The FDA said its draft guidance is designed to prevent the inadvertent substitution of non-interchangeable products and to make it easier to monitor and track usage once…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologics & BiosimilarsdrugFDAFood and Drug AdministrationRegulation

Ustekinumab Found to Be Effective in Adolescents with Psoriasis

Rob Goodier  |  August 27, 2015

NEW YORK (Reuters Health)—Adolescents with moderate to severe psoriasis may respond to the human monoclonal antibody ustekinumab as well as adults, with no unexpected side effects, a new study found. The findings are exciting in part because patients in this age group have limited treatment options, the study’s lead author Dr. Ian Landells, of Memorial…

Filed under:Biologics/DMARDsDrug Updates Tagged with:AdolescentsPsoriasisustekinumab

  • « Previous Page
  • 1
  • …
  • 55
  • 56
  • 57
  • 58
  • 59
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences